We are live on ! Find out more
EDIT icon

Editas Medicine
EDIT

99 hedge funds and large institutions have $614M invested in Editas Medicine in 2017 Q1 according to their latest regulatory filings, with 35 funds opening new positions, 32 increasing their positions, 17 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 15

88% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 17

61% more capital invested

Capital invested by funds: $381M → $614M (+$233M)

18% more funds holding

Funds holding: 84 → 99 (+15)

3.54% more ownership

Funds ownership: 64.09% → 67.63% (+3.5%)

31% less call options, than puts

Call options by funds: $5.38M | Put options by funds: $7.75M

50% less funds holding in top 10

Funds holding in top 10: 4 → 2 (-2)

Holders
99
Holders Change
+15
Holders Change %
+17.86%
% of All Funds
2.46%
Holding in Top 10
2
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-50%
% of All Funds
0.05%
New
35
Increased
32
Reduced
17
Closed
15
Calls
$5.38M
Puts
$7.75M
Net Calls
-$2.37M
Net Calls Change
-$2.61M

Top Buyers

1
Capital World Investors
Capital World Investors
California
+$30.6M
2
BlackRock
BlackRock
New York
+$23.2M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$12.8M
4
Millennium Management
Millennium Management
New York
+$11.5M
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$8.35M

Top Sellers

1
EC
EcoR1 Capital
California
-$10.2M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$4.76M
3
FCMI
Foresite Capital Management III
California
-$4.46M
4
FP
Flagship Pioneering
Massachusetts
-$1.64M
5
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$1.54M
Name Holding Trade Value Shares
Change 		Change in
Stake
FCMI
101
Foresite Capital Management III
California
– -$4.46M -274,910 Closed
Balyasny Asset Management
102
Balyasny Asset Management
Illinois
– -$1.54M -94,800 Closed
Norges Bank
103
Norges Bank
Norway
– -$1.48M -91,102 Closed
OFM
104
Omega Fund Management
Massachusetts
– -$1.07M -66,162 Closed
HP
105
Harbourvest Partners
Massachusetts
– -$590K -36,362 Closed
ARTA
106
A.R.T. Advisors
New York
– -$417K -25,700 Closed
Bessemer Group
107
Bessemer Group
New Jersey
– -$354K -21,818 Closed
SG Americas Securities
108
SG Americas Securities
New York
– -$319K -19,641 Closed
HLA
109
Hamilton Lane Advisors
Pennsylvania
– -$314K -19,323 Closed
Russell Investments Group
110
Russell Investments Group
United Kingdom
– -$284K -17,647 Closed
HTC
111
Hershey Trust Company
Pennsylvania
– -$118K -7,273 Closed
TRCT
112
Tower Research Capital (TRC)
New York
– -$12K -745 Closed
IP
113
Intellectus Partners
California
– -$8K -500 Closed
ECM
114
Elgethun Capital Management
South Dakota
– -$3K -200 Closed
1 2 3 4
5

EDIT Hedge Fund Activity: Q1 2017 in Review

99 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Editas Medicine (EDIT) for Q1 2017, worth a combined $614M — up 61% from $381M a quarter earlier.

Buyers outnumbered sellers: 35 funds opened new EDIT positions and 15 closed out — a net gain of 20 holders — while 32 added to existing stakes and 17 trimmed.

The largest buyer was Capital World Investors, adding an estimated $30.6M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $10.2M sold.

  • 99 institutional investors held Editas Medicine (EDIT) as of Q1 2017, up from 84 in Q4 2016.
  • Funds reported $614M of Editas Medicine stock for Q1 2017, up 61% quarter-over-quarter.
  • 35 funds opened new Editas Medicine positions in Q1 2017 and 15 closed out, a net change of +20 holders.
  • The largest Editas Medicine buyer in Q1 2017 was Capital World Investors, an estimated $30.6M added.
  • The largest Editas Medicine seller in Q1 2017 was EcoR1 Capital, an estimated $10.2M sold.

Based on aggregated 13F filings for Q1 2017.